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For most patients with acute ischaemic stroke, the odds of benefit from intravenous alteplase 
decline steeply over the first 4.5 hours.1 This decay curve is derived from trials in which all 
participants were selected on the basis of non-contrast computed tomography (NCCT), which is 
widely available and valuable to exclude haemorrhage or other structural contraindications to 
treatment. However, NCCT has inherently low sensitivity to early ischemic changes and limited 
ability to discriminate irreversibly damaged from viable tissue. 
Arrival at hospital outside the 4.5h time window or uncertainty about time of onset, most commonly 
due to waking with stroke, have restricted eligibility for intravenous thrombolysis.2 More advanced 
physiological imaging has suggested that this short time window may be too conservative for some, 
including those “slow progressors”3  with favourable leptomeningeal collateral circulation who are 
able to sustain a small core / large penumbra perfusion pattern (the “target mismatch” profile) over 
longer periods of time.  
Wide variation among sites in imaging protocols, inconsistent post-processing, and small sample 
sizes, likely contributed to unsuccessful initial efforts to utilise physiological imaging biomarkers for 
thrombolysis eligibility   beyond the 3 or 4.5 hour window  based on CT perfusion (CTP) or Magnetic 
Resonance Imaging (MRI) diffusion-perfusion mismatch patterns  (Table).   
The imaging criteria used to identify the optimal responder population were initially variable16 but 
have been refined with successive trials, and have been exploited successfully in several recent 
reperfusion trials. Among those with CTP-defined “target mismatch,” tenecteplase has been shown 
to be potentially superior to alteplase,17, 18 while in trials of mechanical thrombectomy (MT) (all 
EXTEND-IA,19 and many SWIFT-Prime20 patients) effect sizes were larger with perfusion imaging 
selection compared to trials that used NCCT brain imaging alone.  
This narrative review did not involve additional data analysis, so no data are available for sharing. 
The EXTEND trial tested the hypothesis that intravenous alteplase improves three-month functional 
outcomes when given in the 4.5-9 h window to patients with salvageable penumbra as defined by a 
commercially available automated software package. The trial used rigorous methodology with a 
relevant primary end-point (mRS 0-1), adjusted for baseline stroke severity. The trial permitted 
inclusion of a broad range of patients (baseline NIHSS score 4-26), with a definition of viable tissue 
(ratio 1.2 or < 10ml difference, <70ml core) more libera than other recent trials. The trial was 
stopped after recruitment of 225 of the 310 planned patients due to loss of equipoise after 
publication of the WAKE-UP trial,11 which demonstrated significant benefit from alteplase  based on 
FLAIR-DWI mismatch criteria. Exclusion of patients in whom mechanical thrombectomy was planned 
presumably led to loss of some recruitment among those fulfilling DAWN or DEFUSE-3 criteria in the 
latter stages.  
Data on how many patients were screened and judged ineligible are unavailable but would be 
relevant for planning systems of care. Prior trials suggest exclusion of around 80% of clinically-
eligible patients by CTP physiological imaging selection.17 MRI FLAIR-diffusion mismatch excluded 
two thirds in the WAKE-UP trial.11 Despite inclusive clinical and radiological criteria, the study 
enrolled moderately severe strokes (median NIHSS 12, approximately 70% having large vessel 
occlusion), with a very favourable ratio between core (2.4-4.6 ml) and hypoperfusion (74-78 ml).  
Intervention and control groups were generally well balanced, but alteplase-treated patients were 
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slightly older, and with more severe strokes as measured by both core volume and NIHSS score. 
Around 65% woke with symptoms present, therefore median onset-to-treatment time of around 7.5 
hours reflects predominantly estimated onset time. The null hypothesis was rejected after pre-
planned adjustment for age and baseline severity (35.4% vs 29.5% achieved mRS 0-1, OR 1.44 (1.01-
2.06). No differences were observed in the mRS distribution analysis, but a higher proportion of 
alteplase-treated patients had major early neurological improvement, attained independent 
recovery (mRS 0-2 at day 90), and had imaging evidence of recanalization and reperfusion at 24h. As 
expected, alteplase-treated patients had an excess of symptomatic intracranial hemorrhage (6.2% 
vs. 0.9%) 
EXTEND,10 and an individual patient data pooled analysis of EXTEND, ECASS-4 and EPITHET,21 provide 
further evidence supporting the concept that tissue viability on physiological imaging should be used 
for reperfusion therapy selection beyond the 4.5 h window or when onset time is uncertain, adding 
to 1021evidence from WAKE-UP,11 DAWN14 and DEFUSE-3.15 . EXTEND offers a longer time window for 
intervention in some by calculating estimated onset time as mid-way between last being well and 
imaging, whereas WAKE-UP required treatment within 4.5h of symptom recognition. The use of the 
same CTP technology often employed to screen for mechanical thrombectomy eligibility is a 
logistical strength. It remains unanswered whether thrombolytic drugs should be administered to 
late-window LVO patients eligible for MT when MT is immediately available, since that scenario was 
not tested in EXTEND. 
EXTEND consolidates the concept of determining treatment eligibility based on physiological imaging 
rather than NCCT and the clock. Perfusion-based selection, as deployed in EXTEND, or MRI-based 
selection as per WAKE-UP, offer alternative imaging selection strategies that should be widely 
deployed for patient benefit. These findings significantly advance stroke treatment, but at the 
expense of additional complexity that will likely require review of systems of care. Triage decisions 
are likely to be dictated by locally available human expertise, imaging and interventional resources. 
Perfusion analysis equipment, software and technicians are expensive resources that might not be 
immediately available in smaller hospitals. For institutions delivering intravenous thrombolysis for 
stroke, acquiring automated imaging capabilities will allow treatment of late time window patients, 
as well as rapid LVO detection with bridging intravenous thrombolysis while in transit to 
thrombectomy-capable institutions. . The trial findings should further stimulate policymakers to 
consider resource distribution across regional networks to ensure optimal delivery of stroke care. 
While these advances clearly expand the options for intravenous thrombolysis for late arrivals and 
for strokes of uncertain onset time, we must avoid any misperception that stroke is less of an 
emergency. Time is still brain, and the emphasis should remain on expediting treatment in the face 
of growing imaging complexities that inform critical triage and transfer decisions. 
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Table: Previous randomised clinical trials of intravenous thrombolysis and thrombectomy based on 
imaging biomarkers in extended time windows (>4.5h since onset). 
 
Trial Year Time Window Imaging Methods 
Intravenous Thrombolysis 
DIAS4 2005 3-6h MRI diffusion-perfusion mismatch 
DEDAS5 2006 3-9h MRI diffusion-perfusion mismatch 
EPITHET6 2008 3-9h MRI diffusion-perfusion mismatch 
DIAS-27 2009 3-9h MRI diffusion-perfusion mismatch or CTP 
DIAS-38 2015 3-9h Intracranial large vessel occlusion 
DIAS-49 2016 3-9h Intracranial large vessel occlusion 
EXTEND10 2018 4.5-9h CTP 
WAKE-UP11 2018 4.5h after 
waking 
MRI diffusion-FLAIR mismatch 
ECASS-412 2019 4.5-9h MRI diffusion-perfusion mismatch 
Mechanical Thrombectomy 
MR RESCUE13 2013 8h MRI diffusion-perfusion mismatch 
DAWN14 2018 6-24h CTP defined core, or MRI DWI core 
DEFUSE-315 2018 6-16h Defined core and mismatch ratio on 
either CTP or MRI 
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